Key result
CT-derived adipose tissue attenuation was negatively correlated with subcutaneous (r = -0.46) and visceral (r = -0.67) fat cell weight, explaining most of the cardiometabolic risk associated with adipocyte hypertrophy.
Why the study?
Do CT-derived measurements of adipose tissue attenuation and area predict fat cell hypertrophy and cardiometabolic risk in women?
Cross-Sectional (n=241)
No
Do CT-derived measurements of adipose tissue attenuation and area predict fat cell hypertrophy and cardiometabolic risk in women?
CT-derived adipose tissue attenuation and area can non-invasively predict visceral fat cell hypertrophy and its associated cardiometabolic risk profile in women.
May support CT assessment of fat cell hypertrophy in women; leaves open prospective validation for cardiometabolic risk.
OBJECTIVE: To assess the ability of CT-derived measurements including adipose tissue attenuation and area to predict fat cell hypertrophy and related cardiometabolic risk. METHODS: Abdominal adipose tissue areas and radiologic attenuation were assessed using 4 CT images in 241 women (age: 47 years, BMI: 26.5 kg/m(2)). Fat cell weight was measured in paired VAT and SAT samples. Fasting plasma lipids, glucose and insulin levels were measured. RESULTS: Adipose tissue attenuation was negatively correlated with SAT (r=-0.46) and VAT (r=-0.67) fat cell weight in the corresponding depot (p<0.0001 for both). Women with visceral adipocyte hypertrophy had higher total-, VLDL-, LDL- and HDL-triglyceride and apoB levels as well as a higher cholesterol/HDL-cholesterol ratio, fasting glucose and insulin levels compared to women with smaller visceral adipocytes. Adjustment for VAT area minimized these differences while subsequent adjustment for attenuation eliminated all differences, with the exception of fasting glycaemia. In SAT, adjustment for VAT area and attenuation eliminated all adipocyte hypertrophy-related alterations except for fasting hyperglycaemia. CONCLUSION: CT-derived adipose tissue attenuation and area both contribute to explain variation in the cardiometabolic risk profile associated with the same biological parameter: visceral fat cell hypertrophy.
No takes yet. Share an insight, caveat, or question.
Côté et al. (2015) conducted a cross-sectional in Visceral obesity and cardiometabolic risk (n=241). CT-derived adipose tissue attenuation and area was evaluated on Correlation between adipose tissue attenuation and fat cell weight in SAT and VAT (r = -0.46 (SAT) and r = -0.67 (VAT), p=<0.0001). CT-derived adipose tissue attenuation was negatively correlated with subcutaneous (r = -0.46) and visceral (r = -0.67) fat cell weight, explaining most of the cardiometabolic risk associated with adipocyte hypertrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: